High-Price Cancer Drug Prices: The Harm to Americans and Proposed Solutions
January 20, 2017 | Hagop M. Kantarjian, Vivian Ho

Table of Contents
Author(s)
Hagop M. Kantarjian
Nonresident Fellow in Health PolicyVivian Ho
James A. Baker III Institute Chair in Health EconomicsHigh cancer drug prices significantly contribute to health care costs in the United States, with the average annual price of new cancer drugs increasing from less than $10,000 before 2000 to $145,000 in 2015. Baker Institute fellows Hagop M. Kantarjian and Vivian Ho highlight this issue and propose possible solutions.
This policy brief is part of a series of recommendations from the Baker Institute for the incoming president’s administration.